Risk factors and predictors that influence SARS-Cov-2 IgG positivity

Alosaimi, Mohammed F.; Alhetheel, Abdulkarim; Aleisa, Khalid Abdullah; Altwerki, Abdullah A; Alenezy, Njoud M; Almutairi, Ebtisam M; Alothaim, Leen O; Khalid, Abdul Manan A; Alayed, Khalid; Almazyad, Mohammed; Binmoammar, Turki A; Alshobaili, Fahdah A; Alshahrani, Fatimah; Alsubaie, Sarah; Hasanato, Rana

doi:10.15537/smj.2021.42.8.20210238

Cited by 2 publications

(1 citation statement)

References 47 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the seroprevalence rates observed by us were higher in comparison to the other seroprevalences among the blood donors reported by other countries during November and December 2020. [ 15 16 17 18 19 ] This could be attributed to differences in the epidemiological profile of the COVID-19 positive populations in our country. [ 20 ] In our study majority of the blood donors were males, with equivalent proportions of first-time and repeat donors, from the urban areas of the country with no major difference from the pre-COVID era among the age/gender, urban/rural population.…”

Section: Discussionmentioning

confidence: 99%

Epidemiology of severe acute respiratory syndrome-related coronavirus 2 antibodies in healthy blood donors and their follow-up

Patidar¹,

Chaurasia²,

Pandey³

et al. 2023

Asian J Transfus Sci

View full text Add to dashboard Cite

BACKGROUND: Asymptomatic/presymptomatic COVID-19 affected individuals who may appear healthy during blood donor screening can donate blood despite being infective. Most blood donors in India are relatives/friends/acquaintances of patients, who under peer pressure overlook the donor selection process, which can significantly impact the transfusion safety. AIMS: The prevalence of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) antibodies among blood donors was assessed, along with the possible transmissibility of SARS-CoV-2 virus in transfusion recipients of blood components prepared from sero-reactive blood donors. SETTINGS AND DESIGN: A prospective cross-sectional study was conducted among eligible blood donors from November-2020 to April 2021. METHODS: 1500 blood donors were tested for SARS-CoV-2 IgG antibodies. Sero-reactive donors were followed-up telephonically to inquire about risk factors prior to donation or appearance of COVID-19 related symptoms postdonation. Patients transfused with blood components from seroreactive donors were also followed up for posttransfusion symptoms suggestive for COVID-19. Descriptive analysis was done for the donor and patient follow-up data. RESULTS: A total of 452 (30.1%) donor were reactive, with median S/CO ratio of 2.8 (interquartile range 1.5–5.5). Risk factors such as travel, contact, or quarantine were significantly higher among reactive donors. History of diabetes and/or hypertension was associated with seroreactivity. Total 516 patients were transfused with blood components from these seroreactive donors. Three patients developed fever after transfusion, one of which was found to be PCR positive after 4 days of transfusion. CONCLUSION: Sero-reactivity rate among blood donors was lower than the general population. Optimum blood donor screening strategies can help decrease the possibility of blood collection from infected blood donors.

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiology of severe acute respiratory syndrome-related coronavirus 2 antibodies in healthy blood donors and their follow-up

Patidar¹,

Chaurasia²,

Pandey³

et al. 2023

Asian J Transfus Sci

View full text Add to dashboard Cite

show abstract

Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors: a systematic review and meta-analysis

Ukwishaka,

Fotabong,

Aseneh

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction: The development of a potent immune response and antibodies against SARS-CoV-2 is important for attaining herd immunity. This serological response could be due to past infection or vaccines. Healthy blood donors could represent and provide information on the immune status of the general population. Hence, we estimated the global and regional prevalence of SARS-CoV-2 antibodies among healthy asymptomatic blood donors. Methods: We systematically searched PubMed, Scopus, and ProQuest for eligible articles published between December 1, 2019, and January 12, 2023, without language restrictions. After critical appraisal and quality assessment, a qualitative synthesis of the identified pertinent articles was performed. The random-effect model was used to estimate the pooled prevalence of SARS-CoV-2 antibodies. Funnel plots and Egger’s test were used to assess publication bias. Sensitivity analysis was performed, and heterogeneity was quantified using I2 statistics. Results: A total of 70 peer-reviewed articles were selected and included 2,453,937 blood donors. The global estimated pooled prevalence of SARS-CoV-2 antibodies among healthy blood donors was 10.9% (95% CI: 5.0 – 18.8%, n=68). A high seroprevalence of SARS-CoV-2 was observed in Asia (20.4%, 95% CI: 10.1 – 33.1%, n=24), followed by Africa (16.1%, 95% CI: 6.8 – 28.3%, n=7). The seroprevalence of SARS-CoV-2 in studies conducted before the introduction of the vaccine was 6.5% (95% CI: 4.9 – 8.3%, n=50), while that of studies conducted after the vaccine was 27.6% (95% CI: 12.4 – 46.2% n=18). High seroprevalence was observed in studies that measured antibodies against the S protein of the virus (16.2%, 95% CI: 11.4 – 21.8%, n=27), while it was 12.5% (95% CI: 5.3 – 22.1%, n=16) in those that measured antibodies against the N protein. A high seroprevalence of SARS-CoV-2 was observed in studies that only measured IgG antibodies (17.2%, 95% CI: 10.5 – 25.1%, n=33) and in studies that measured total antibodies to SARS-CoV-2 (6.2%, 95% CI: 0.7 – 16.5%, n=33). Conclusion: In view of all evidence, there is variation in the prevalence of SARS-CoV-2 antibodies among healthy blood donors globally. Noticeably, there is a regional difference that could depict differences in transmission and vaccination rates. Based on the results of our analysis, we recommend evidence-based booster vaccination strategies informed by seroprevalence trends and waning immunity and reinforcing seroprevalence surveillance for outbreak management. It is advisable to mitigate socioeconomic disparities through inclusive health policies coupled with adaptable public health measures given local seroprevalence rates. These will contribute to informed policy decisions to build community resilience during the post-PHEIC phase of the COVID-19 pandemic.

show abstract

Risk factors and predictors that influence SARS-Cov-2 IgG positivity

Abstract: Objectives: To study the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after pandemic's peak and before the vaccine enrollment in Riyadh, Saudi Arabia and further explore predictors for SARS-CoV-2 positivity.

Cited by 2 publications

References 47 publications

Epidemiology of severe acute respiratory syndrome-related coronavirus 2 antibodies in healthy blood donors and their follow-up

Epidemiology of severe acute respiratory syndrome-related coronavirus 2 antibodies in healthy blood donors and their follow-up

Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors: a systematic review and meta-analysis

Contact Info

Product

Resources

About